Short-term antibiotic therapy with clindamycin phosphate in patients with malignant epithelial tumors: an immunological evaluation.
The authors evaluated the results of a study using clindamycin phosphate plus gentamicin in short-term therapy in patients with tumors submitted to surgery for removal of the primary lesion. Only 6.6% of these patients became infected, and these good results are most likely due to the synergic activity of clindamycin with the physiological immune response. This agent, in fact, was able to interfere with IgM/IgA immunoregulatory balance by enhancing IgM production and, consequently, phagocytic mechanisms.
D002981:Clindamycin / Q000627:therapeutic use*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000601:surgery*; D011292:Premedication; D013997:Time Factors
D005839:Gentamicins; D007136:Immunoglobulins; D002981:Clindamycin